(NASDAQ: OTLK) Outlook Therapeutics's forecast annual revenue growth rate of 384.07% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.6%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.68%.
Outlook Therapeutics's revenue in 2026 is $333,141.On average, 6 Wall Street analysts forecast OTLK's revenue for 2026 to be $2,327,947,097, with the lowest OTLK revenue forecast at $236,891,974, and the highest OTLK revenue forecast at $5,840,474,926. On average, 6 Wall Street analysts forecast OTLK's revenue for 2027 to be $5,637,303,800, with the lowest OTLK revenue forecast at $1,658,243,817, and the highest OTLK revenue forecast at $16,833,833,739.
In 2028, OTLK is forecast to generate $2,815,267,729 in revenue, with the lowest revenue forecast at $2,704,798,717 and the highest revenue forecast at $2,898,059,056.